% | $
Quotes you view appear here for quick access.

DARA Biosciences, Inc. Message Board

  • woodbarn woodbarn Feb 13, 2013 2:16 PM Flag

    Rosemont Pharmaceuticals sold to Perrigo. DARA license Soltamox from Rosemont.

    Rosemont Pharmaceuticals sold to Perrigo Feb-11-2013. If you do not know, Rosemont is company that Soltamox is licensed from. Press release says company had about $60 million sales in 2012 over 90 products. Now we get an idea of how large oral liquid market is in U.K.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Folks dont let wood4brains scare you as he owns no shares and has not intentions to ever speak positively about Dara or Soltamax. Here's the facts regarding the Rosemont aquisition.

      First it was a positive aquisition and if it were not then Perrigo would not have aquired Rosemont in the first place. Secondly the reformulation effort and more importantly the distribution of Soltamox is going well and according to plan. Finally and this is very important based on the aquisition of Rosemont Perrigo will likely be the oral liquid distributor for DARA and yes they Perrigo are now the big dog on campus....woody get your facts straight and tell the damn whole story for once..Read on people and don't miss the train.

      Key benefits of the transaction as cited by Perrigo include:

      • Expansion in an attractive specialty market - Rosemont's portfolio of liquid formulations addresses a critical medicinal need within pediatrics, as well as for those patients with dysphagia (swallowing difficulties), a common malady in a growing elderly population;

      • Immediate access to oral liquid formulations - The transaction is aligned with Perrigo's strategic growth objective to expand into additional liquid categories and diversified prescription medicines to further broaden its customer product portfolio;

      • Perrigo gains a leadership position in a large and growing market - Favorable demographic drivers have been increasing demand for easier-to-swallow products. Rosemont's leading position in that market, combined with a strong pipeline of products and access to under-penetrated international markets, represents an exciting opportunity for future growth and European expansion;

      • Opportunity for synergy - The acquisition allows Perrigo to expand its U.K. portfolio while leveraging its established distribution and administrative infrastructures and long standing customer relationships.

      Perrigo is considered the world's largest maker of over-the-counter pharmaceutical products for the store brand market. It manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients.

0.880.00(0.00%)Dec 4 3:59 PMEST